Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

BACKGROUND: Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival. METHODS: Patients treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Alghamdi, Mohammed A., Amaro, Carla P., Lee‐Ying, Richard, Sim, Hao‐Wen, Samwi, Haider, Chan, Kelvin K., Knox, Jennifer J., Ko, Yoo‐Joung, Swiha, Mina, Batuyong, Eugene, Romagnino, Adriana, Cheung, Winson Y., Tam, Vincent C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367626/
https://www.ncbi.nlm.nih.gov/pubmed/32529797
http://dx.doi.org/10.1002/cam4.3228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367626/
https://www.ncbi.nlm.nih.gov/pubmed/32529797
http://dx.doi.org/10.1002/cam4.3228

Ejemplares similares